Perinatal Mood and Anxiety Disorders (PMADs) are the #1 complication of pregnancy — yet most go undiagnosed and untreated. Nyx Health is changing that.
Affecting more than 1 in 5 pregnant and postpartum women, Perinatal Mood and Anxiety Disorders represent a hidden epidemic — one that carries severe consequences for both mother and child when left untreated.
Tracing the journey from prevalence to remission reveals a system that loses patients at every step. Both Antenatal Depression (AND) and Postpartum Depression (PPD) show alarming drop-offs before adequate care is reached.
Untreated PMADs generate enormous economic burden — spanning maternal healthcare, child outcomes, and lost productivity. This cost is largely preventable.
US maternal mortality has worsened for decades — and the racial gap is stark. Black women face mortality rates 2–3× higher than white women, and the US trails far behind peer nations globally.
Structural racism, implicit bias in clinical settings, and barriers to mental health access drive this preventable disparity. AI-powered tools must be built with equity at their core.
Nyx Health is building the next generation of AI-powered tools for early PMAD detection, continuous monitoring, and personalized intervention. We're looking for partners, clinicians, and investors.
Get in Touch